Haw ParHAWPF 95 Current Ratio is 52.24 as of Dec. 2025, which is 22% above its 10-year median of 42.89. GuruFocus rates HAWPF with a GF Score™ of 95/100 and a GF Value™ of $8.79. The stock has 3 warning signs investors should review. Among 998 Drug Manufacturers companies, Haw Par ranks better than 99.5% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Haw Par's current ratio for the quarter that ended in Dec. 2025 was 52.24.
Haw Par has a current ratio of 52.24. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Haw Par's Current Ratio or its related term are showing as below:
HAWPF'
s Current Ratio Range Over the Past 10 Years
Min: 21.73 Med: 42.89 Max: 52.24
Current: 52.24
During the past 13 years, Haw Par's highest Current Ratio was 52.24. The lowest was 21.73. And the median was 42.89.
HAWPF's Current Ratio is ranked better than 99.5% of 998
companies
in the Drug Manufacturers industry
Industry Median: 1.995
vs HAWPF: 52.24
Haw Par (OTCPK:HAWPF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Haw Par Current Ratio Related Terms
Haw Par Current Ratio Historical Data
* Premium members only.
The historical data trend for Haw Par's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Haw Par's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haw Par Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Haw Par's Current Ratio distribution charts can be found below:
* The bar in red indicates where Haw Par's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haw Par (HAWPF) has a Current Ratio of 52.24 as of Dec. 2025. This is 22% above median its historical median of 42.89. Over the past decade, Haw Par's Current Ratio has ranged from 21.73 to 52.24. According to the industry distribution chart, Haw Par ranks #5 out of 998 companies in the Drug Manufacturers industry, placing it in the top 0.5%.
Is Haw Par's Current Ratio too high?
Haw Par's current Current Ratio of 52.24 is 22% above median its 10-year median of 42.89. Over the past 10 years, this metric has ranged from a low of 21.73 to a high of 52.24. The Drug Manufacturers industry median Current Ratio is 2.00. Haw Par's value of 52.24 is 2518.5% above this industry median. Based on the distribution chart, Haw Par ranks #5 out of 998 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Haw Par has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Haw Par's Current Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Haw Par ranks #5 out of 998 companies for Current Ratio. This places Haw Par in the top 1% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.00. Haw Par's value of 52.24 is 2518.5% above this benchmark. Historically, Haw Par's own Current Ratio has ranged from 21.73 to 52.24 over the past decade. While the company's 10-year median is 42.89 vs. the industry median of 2.00, Haw Par has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haw Par's current Current Ratio of 52.24 is 2518.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haw Par's current Current Ratio is 52.24, which is 22% above median its own 10-year median of 42.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haw Par stock overvalued right now?
Haw Par (HAWPF) has a current Current Ratio of 52.24. The stock's GF Value™ is $8.79, compared to a current price of $12.00 — trading 36.5% above its estimated fair value. The current Current Ratio is 52.24, which is 22% above median its 10-year median of 42.89 and 2518.5% above the Drug Manufacturers industry median of 2.00. Haw Par's overall GF Score™ is 95/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Haw Par (HAWPF), the current Current Ratio is 52.24 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haw Par (HAWPF) Overvalued in 2026?
Based on GuruFocus' analysis, Haw Par stock appears to be overvalued.
The current stock price of $12.00 is trading 36.5% above its estimated GF Value™ of $8.79.
Key valuation signals for HAWPF:
Current Ratio: 52.24 (22% above median its 10-year median of 42.89)
GF Value™: $8.79 vs. price of $12.00 (36.5% above fair value)
Industry Position: 2518.5% above the Drug Manufacturers median (#5 of 998)
No single metric tells the full story. See the HAWPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haw Par Corp Ltd is a drug manufacturing company that operates multiple brands. The company is to expand its core businesses through product brand extension, strategic alliances, and exploring potential acquisitions. Its operating segments include the Healthcare segment, Investments segment, Property segment, and Leisure segment. The company generates the majority of its revenue from the Healthcare segment. Its Healthcare segment manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands. Geographically, it generates key revenue from the other ASEAN and other Asian countries.
95GF Score
Get the complete analysis for HAWPF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAWPF has been successfully added to your 
